MF59 adjuvant
Sponsors
Robert Pass, MD, National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority
Conditions
Avian InfluenzaCytomegalovirus InfectionsImmunisationInfluenzaInfluenza A Virus, H5N1 Subtype
Phase 1
Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults
CompletedNCT00133471
Start: 2005-03-31End: 2005-12-31Updated: 2010-08-27
H5N1 Mix and Match With MF59
CompletedNCT01317745
Start: 2011-05-31End: 2012-09-30Updated: 2013-01-25
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
CompletedNCT02251288
Start: 2015-05-18End: 2018-08-17Updated: 2020-01-27
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
CompletedNCT02624219
Start: 2016-08-16End: 2018-01-30Updated: 2019-10-23
Phase 2
Recombinant CMV gB Vaccine in Postpartum Women
CompletedNCT00125502
Start: 1999-08-31End: 2010-01-31Updated: 2011-09-20
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
CompletedNCT03497845
Start: 2018-03-15End: 2019-11-19Updated: 2020-07-14